Attached files
file | filename |
---|---|
EX-99.1 - PRESS RELEASE - Acer Therapeutics Inc. | opxa_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (date of earliest event reported): May 12,
2017
OPEXA THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Texas
|
|
001-33004
|
|
76-0333165
|
(State
or other jurisdiction ofincorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
2635 Technology Forest Blvd., The Woodlands, Texas
|
|
77381
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
|
||
Registrant’s
telephone number, including area code: (281) 272-9331
|
||
N/A
|
||
(Former
name or former address, if changed since last report)
|
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of
1934 (§240.12b-2 of this chapter).
Emerging
growth company ☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange
Act. ☐
Item
2.02. Results of Operations and Financial
Condition.
On May
12, 2017, Opexa Therapeutics, Inc. filed its Quarterly Report on
Form 10-Q for the quarter ended March 31, 2017 and announced its
results of operations in a press release. A copy of the press
release announcing the results is furnished as Exhibit 99.1 to this
Current Report on Form 8-K and is incorporated herein by
reference.
Item
9.01. Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit No.
|
|
Description
|
|
|
|
|
Press release
issued by Opexa Therapeutics, Inc. on May 12, 2017.
|
The information in Item 2.02 of this Current Report on Form 8-K,
including Exhibit 99.1, shall not be deemed
“filed” for the purposes of Section 18 of the
Securities Exchange Act of 1934 or otherwise subject to the
liabilities under that Section, nor be deemed to be incorporated by
reference into the filings of the registrant under the Securities
Act of 1933.
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
|
OPEXA THERAPEUTICS, INC. |
|
|
Dated: May 12,
2017 |
|
|
|
|
By:
|
/s/
Neil K.
Warma
|
|
|
|
Neil K.
Warma
|
|
|
|
President, Chief
Executive Officer and
Acting Chief
Financial Officer
|
|
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
|
Press release
issued by Opexa Therapeutics, Inc. on May 12, 2017.
|